← All trials
NCT04187443
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 4, 2020
- Primary completion
- Aug 18, 2021
- Completion date
- Oct 18, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MingSight-Relin Pharmaceuticals Co., Ltd.Lead sponsor
- MingSight-Relin Pharmaceuticals Co., Ltd.Study director
- Fountain Medical Development Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.